#AS­CO21: Gilead­'s Trodelvy reads out new sub­group da­ta show­ing ben­e­fit in ear­li­er-line TNBC pa­tients

5 years ago
R&D

#AS­CO21: SQZ of­fers first clin­i­cal glimpse of un­ortho­dox cell ther­a­py man­u­fac­tur­ing tech — but check­point com­bo is ...

5 years ago
R&D
Cell/Gene Tx

Bris­tol My­ers sued over $6B Cel­gene CVR as trustee claims 'bla­tant mis­con­duc­t' for liso-cel de­lays

5 years ago
Pharma

'Au­ton­o­my with bridges': The chief ar­chi­tect of the Alex­ion buy­out is now head­ed over to take com­mand. Here's what ...

5 years ago
Deals

Re­gen­eron con­tin­ues reign atop the Covid treat­ment field with ex­pand­ed EUA for low­er dose sub­cu­ta­neous ver­sion of mAb ...

5 years ago
FDA+
Coronavirus

#AS­CO21: Co­herus, Jun­shi hunt US ap­proval for an­ti-PD-1 drug in nose and throat can­cer with late-stage win

5 years ago
R&D

#AS­CO21: Nanobi­otix says ear­ly da­ta show 'very strong' sig­nal that its nanopar­ti­cles can di­al up an­ti­tu­mor re­sponse

5 years ago
R&D

#AS­CO21: Bris­tol My­er­s' so­lo, dual I/O reg­i­mens best chemo alone — with one ex­cep­tion — in first-line esophageal ...

5 years ago
R&D

#AS­CO21: As­traZeneca's Lyn­parza earns win in ear­ly breast can­cer pa­tients, crack­ing open post-surgery po­ten­tial

5 years ago
R&D
Pharma

#AS­CO21: Mer­ck keeps chop­ping away at a path to ear­ly can­cer pa­tients for Keytru­da, this time in kid­ney

5 years ago
R&D

Just months af­ter SPAC re­verse merg­er, Point Bio­phar­ma ups the ante at In­di­anapo­lis man­u­fac­tur­ing site

5 years ago
R&D
Manufacturing

As com­pa­nies dump mon­ey in­to man­u­fac­tur­ing, where will they find the trained work­ers to staff the lines?

5 years ago
Manufacturing

Aa­van­tiBio lands man­u­fac­tur­ing part­ner in Friedre­ich's Atax­ia pro­gram; NC Re­search Tri­an­gle lands an­oth­er CD­MO

5 years ago
R&D
Manufacturing

A Bel­gian man­u­fac­tur­er looks to pit its freeze dry­ing process against mR­NA — and be­yond

5 years ago
R&D
Manufacturing

As the mR­NA push con­tin­ues, Sam­sung will ex­pand its drug sub­stance man­u­fac­tur­ing at South Ko­re­an hub

5 years ago
Coronavirus
Manufacturing

Covid-19 man­u­fac­tur­ing roundup: Af­ter Emer­gent dis­as­ter, As­traZeneca in talks to move to Catal­ent plant — re­port; ...

5 years ago
R&D
Manufacturing

#AS­CO21: No­var­tis flash­es 'ground­break­ing data' for $2B ra­di­oli­gand drug

5 years ago
R&D

Bio­phar­ma sup­ply chain se­cu­ri­ty: FDA guid­ance spells out new ex­pec­ta­tions

5 years ago
FDA+

Am­ryt earns a pri­or­i­ty re­view in a rare dis­ease that makes pa­tients' skin frag­ile as but­ter­fly wings

5 years ago
FDA+

Mer­ck­'s wom­en's health spin­off goes pub­lic in NYSE de­but; A Hous­ton an­ti­body play­er scores fresh funds to chase ...

5 years ago
News Briefing

Corey Good­man's ven­Bio clos­es lat­est VC fund — this time to the tune of $550M — with a dozen or more in­vest­ments ...

5 years ago
Financing

For­mer FDA No. 2 Amy Aber­nethy re­joins Robert Califf at Google's Ver­i­ly, hop­ping aboard as clin­i­cal R&D head

5 years ago
People
FDA+

Af­ter ad­mon­ish­ing Ab­b­Vie for Hu­mi­ra patent and pric­ing, Sen Ron Wyden takes Richard Gon­za­lez to task on tax prac­tices

5 years ago
Pharma

Scynex­is will pit a new class of an­ti­fun­gals against yeast in­fec­tions — and it won't come cheap

5 years ago
FDA+
First page Previous page 694695696697698699700 Next page Last page
A service from the Financial Times